查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712497

日本CAR-T細胞療法市集—2025-2033

Japan CAR-T Cell Therapies Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年日本 CAR-T 細胞療法市場規模達到 3.46 億美元，預計到 2033 年將達到 13.5015 億美元，在 2025-2033 年預測期內的複合年成長率為 16.3%。

CAR-T 細胞療法，即嵌合抗原受體 T 細胞療法，是一種主要用於癌症治療的先進免疫療法。它涉及對患者的 T 細胞（一種免疫細胞）進行改造，透過修飾它們來表達嵌合抗原受體 (CAR)，從而使這些細胞能夠識別和攻擊特定的癌細胞。 CAR-T 細胞療法對某些血癌特別有效，例如急性淋巴性白血病 (ALL) 和某些類型的淋巴瘤。

然而，目前正在進行研究以使這種方法適用於實體腫瘤，實體腫瘤面臨不同的挑戰，例如更具抑制性的腫瘤微環境可能會限制 CAR-T 細胞的有效性。 CAR-T 細胞療法的需求正在迅速成長，這得益於其治療晚期血癌的潛力及其提供個人化治療結果的能力。

市場動態：

駕駛員和約束裝置

血液系統癌症發生率上升

日本多發性骨髓瘤、白血病和淋巴瘤等血液系統癌症發生率的上升預計將顯著推動該國 CAR-T 細胞治療市場的成長。隨著日本人口老化，這些血液相關癌症的發生率一直在穩步上升，對先進且有效的治療方案的需求也越來越大。例如，根據國際癌症研究機構提供的資料，2022年日本報告了約6,988例多發性骨髓瘤新病例。預計到2025年，這數字將達到7,350例。此外，預計到2030年日本多發性骨髓瘤發生率將達7,535。

傳統療法在復發或難治性病例中通常收效有限，這增加了對 CAR-T 細胞療法等創新解決方案的需求。這種尖端方法涉及重新編程患者的免疫細胞以瞄準和摧毀癌細胞，為已經用盡標準治療方法的患者帶來了新的希望。隨著人們認知的提高和監管支持的加強，正如最近批准的 CARVYKTI 一樣，日本有望成為亞太地區 CAR-T 細胞療法的主要市場。因此，上述因素正在推動市場成長。

治療費用高昂

CAR-T 細胞療法的高成本限制了患者和醫療保健系統的可近性和可負擔性，嚴重阻礙了其市場成長。成本障礙限制了患者獲得治療的機會，特別是在沒有全面報銷框架的國家，並且限制了該療法的市場滲透。由於缺乏長期成本效益資料，許多醫療保健提供者和保險公司不願承保 CAR-T 細胞療法，因此儘管該療法具有臨床療效，但仍限制了其採用。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按治療類型分類
  • 依藥物類型分類
  • 目標抗原片段
  • 按應用程式截取的程式碼片段

第3章：動態

  • 影響因素
    • 驅動程式
      • 血液系統癌症發生率上升
      • 個人化治療需求不斷成長
    • 限制
      • 治療費用高昂
      • 嚴格的規範架構
    • 機會
      • 臨床研究數量不斷增加
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 北美監管與報銷格局
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：CAR-T細胞療法市場（依療法類型分類）

  • 自體CAR-T細胞療法
  • 同種異體CAR-T細胞療法

第6章：CAR-T細胞療法市場（依藥物類型）

  • 阿貝克瑪
  • 布雷揚齊
  • 卡爾維克蒂
  • 特卡圖斯
  • 基姆裡亞
  • 耶斯卡塔

第7章：CAR-T細胞療法市場（以標靶抗原）

  • CD19
  • BCMA（B細胞成熟抗原）
  • CD20
  • CD22
  • CD30
  • 其他

第 8 章：CAR-T 細胞療法市場（按應用）

  • 急性淋巴母細胞白血病（ALL）
  • 非何杰金氏淋巴瘤
  • 慢性淋巴球白血病
  • 多發性骨髓瘤（MM）
  • 濾泡性淋巴瘤
  • 其他

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Gilead Sciences, Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Bristol Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • 寶生物公司

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: PH9491

The Japan CAR-T cell therapies market reached US$ 346.00 million in 2024 and is expected to reach US$ 1,350.15 million by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

CAR-T cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an advanced immunotherapy used primarily in cancer treatment. It involves engineering a patient's T cells, a type of immune cell, by modifying them to express a chimeric antigen receptor (CAR) that allows these cells to recognize and attack specific cancer cells. CAR-T cell therapy has been particularly effective for certain blood cancers, such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.

However, research is ongoing to adapt this approach for solid tumors, which have different challenges, like a more suppressive tumor microenvironment that can limit CAR-T cell effectiveness. The demand for CAR-T cell therapy is growing rapidly, driven by its potential to treat advanced blood cancers and its ability to deliver personalized treatment outcomes.

Market Dynamics: Drivers & Restraints

Rising Incidence of Hematological Cancers

The rising incidence of hematological cancers in Japan, such as multiple myeloma, leukemia, and lymphoma, is expected to significantly drive the growth of the country's CAR-T cell therapy market. As Japan's population continues to age, the prevalence of these blood-related cancers has been steadily increasing, creating a greater need for advanced and effective treatment options. For instance, according to the data provided by the International Agency for Research on Cancer, around 6,988 new cases of multiple myeloma were reported in Japan in 2022. By 2025, the number is expected to reach 7,350. Also, it is estimated that the incidence of multiple myeloma in Japan is expected to reach 7,535 by 2030.

Traditional therapies often have limited success in relapsed or refractory cases, which is raising the demand for innovative solutions like CAR-T cell therapy. This cutting-edge approach, which involves reprogramming a patient's immune cells to target and destroy cancer cells, offers new hope for patients who have exhausted standard treatments. As awareness grows and regulatory support strengthens, as seen with recent approvals like CARVYKTI, Japan is poised to become a key market for CAR-T cell therapies in the Asia-Pacific region. Thus, the above factors are driving the market growth.

High Costs of Therapy

The high cost of CAR-T cell therapy significantly hampers its market growth by limiting accessibility and affordability for patients and healthcare systems. The cost barrier restricts patient access, especially in countries without comprehensive reimbursement frameworks, and limits the therapy's market penetration. Many healthcare providers and insurers hesitate to cover CAR-T cell therapy due to the lack of long-term cost-benefit data, thus constraining its adoption despite clinical efficacy.

Segment Analysis

The Japan CAR-T cell therapies market is segmented based on the therapy type, drug type, target antigen, and application.

Multiple myeloma in the application segment is expected to dominate the CAR-T cell therapies market

Multiple myeloma is projected to lead the application segment of Japan's CAR-T cell therapy market, driven by the rising number of cancer cases, increasing approval and launch activities from key industry players. For instance, in September 2022, Legend Biotech Corporation, a global biotechnology company focused on developing, manufacturing, and commercializing innovative therapies for life-threatening diseases, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) had approved CARVYKTI (ciltacabtagene autoleucel). This BCMA-targeted CAR-T cell therapy is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma.

Additionally, in December 2023, Bristol Myers Squibb's idecabtagene vicleucel was approved in Japan for patients with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy. The approval was supported by results from the phase 3 KarMMA-3 trial, which showed significant improvements in progression-free survival and objective response rates compared to standard therapies.

These developments underscore the growing focus on multiple myeloma within Japan's CAR-T therapy market. The increasing availability of approved CAR-T treatments is expected to meet the rising demand for effective therapies, solidifying multiple myeloma as a dominant application area in this market segment.

Competitive Landscape

The market players in the CAR-T cell therapies market are Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson Services, Inc., and Novartis AG, among others.

Key Developments

  • In April 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
  • In January 2024, Bristol Myers Squibb announced three regulatory acceptances from the U.S. Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare (MHLW) for Breyanzi (lisocabtagene maraleucel).
  • In April 2023, Takara Bio Inc. submitted a Clinical Trial Application (CTA) to Health Canada and the receipt of the No Objection Letter to initiate a Phase I/Ib clinical trial for CD19 JAK/STAT CAR-T therapy (TBI-2001). Once the necessary steps are taken, the investigator-initiated clinical trial will be started for patients with CD19-positive B-cell lymphoma.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan CAR-T cell therapies market report would provide approximately 42 tables, 33 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Therapy Type
  • 2.4. Snippet by Drug Type
  • 2.5. Snippet by Target Antigen
  • 2.6. Snippet by Application

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Incidence of Hematological Cancers
      • 3.1.1.2. Growing Demand for Personalized Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. High Costs of Therapy
      • 3.1.2.2. Stringent Regulatory Framework
    • 3.1.3. Opportunity
      • 3.1.3.1. Rising Number of Clinical Studies
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. North America Regulatory and Reimbursement Landscape
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. CAR-T cell therapies Market, By Therapy Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 5.1.2. Market Attractiveness Index, By Therapy Type
  • 5.2. Autologous CAR-T Cell Therapy*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Allogeneic CAR-T Cell Therapy

6. CAR-T cell therapies Market, By Drug Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Abecma*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Breyanzi
  • 6.4. Carvykti
  • 6.5. Tecartus
  • 6.6. Kymriah
  • 6.7. Yescarta

7. CAR-T cell therapies Market, By Target Antigen

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 7.1.2. Market Attractiveness Index, By Target Antigen
  • 7.2. CD19*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. BCMA (B-cell maturation antigen)
  • 7.4. CD20
  • 7.5. CD22
  • 7.6. CD30
  • 7.7. Others

8. CAR-T cell therapies Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Acute Lymphoblastic Leukemia (ALL)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-Hodgkin Lymphoma
  • 8.4. Chronic Lymphocytic Leukemia
  • 8.5. Multiple Myeloma (MM)
  • 8.6. Follicular Lymphoma
  • 8.7. Others

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

Established Players

  • 10.1. Gilead Sciences, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Bristol Myers Squibb Company
  • 10.3. Johnson & Johnson Services, Inc.
  • 10.4. Novartis AG

Emerging Players

  • 10.5. Takara Bio Inc

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us